These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34973390)

  • 1. TCR-induced FOXP3 expression by CD8
    Lozano T; Conde E; Martín-Otal C; Navarro F; Lasarte-Cia A; Nasrallah R; Alignani D; Gorraiz M; Sarobe P; Romero JP; Vilas A; Roychoudhuri R; Hervás-Stubbs S; Casares N; Lasarte JJ
    Cancer Lett; 2022 Mar; 528():45-58. PubMed ID: 34973390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
    Lozano T; Villanueva L; Durántez M; Gorraiz M; Ruiz M; Belsúe V; Riezu-Boj JI; Hervás-Stubbs S; Oyarzábal J; Bandukwala H; Lourenço AR; Coffer PJ; Sarobe P; Prieto J; Casares N; Lasarte JJ
    J Immunol; 2015 Oct; 195(7):3180-9. PubMed ID: 26324768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
    Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
    J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
    Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
    Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
    Moran AE; Polesso F; Weinberg AD
    J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.
    Le DT; Ladle BH; Lee T; Weiss V; Yao X; Leubner A; Armstrong TD; Jaffee EM
    Int J Cancer; 2011 Aug; 129(3):636-47. PubMed ID: 20857491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma.
    Conde E; Casares N; Mancheño U; Elizalde E; Vercher E; Capozzi R; Santamaria E; Rodriguez-Madoz JR; Prosper F; Lasarte JJ; Lozano T; Hervas-Stubbs S
    Mol Ther; 2023 Jan; 31(1):48-65. PubMed ID: 36045586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
    Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
    Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
    Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
    Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
    Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
    Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity.
    Mayer CT; Floess S; Baru AM; Lahl K; Huehn J; Sparwasser T
    Eur J Immunol; 2011 Mar; 41(3):716-25. PubMed ID: 21312192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
    Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
    Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Intestinal Inflammation With Epicutaneous Immunotherapy Requires TGF-β and IL-10 but Not Foxp3
    Chen X; Berin MC; Gillespie VL; Sampson HA; Dunkin D
    Front Immunol; 2021; 12():637630. PubMed ID: 33717186
    [No Abstract]   [Full Text] [Related]  

  • 19. Providence of the CD25
    Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
    Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
    Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
    EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.